More than 25 international peer publications (http://www.ncbi.nlm.nih.gov/pubmed?term=Robbe Masselot C; https://www.ncbi.nlm.nih.gov/pubmed/?term=Robbe+C)
Assistant Professor Université Lille1 since 2006 Unité de Glycobiologie Structurale et Fonctionnelle; UMR 8576, CNRS/USTL; Bâtiment C9, Cité Scientifique; 59655 Villeneuve d’Ascq
2012 Accreditation to supervise PhD students (HDR), Université Lille1
2003 Thèse de doctorat (PhD), Université Lille1, in Biochemistry
2000 Master (DEA "Sciences de la Vie et de la Santé), Université Lille1
Since 2006 Maître de Conférences (assistant professor) at Université Lille 1
2005-2006 Attachée temporaire d’enseignement et de recherche, Université Lille 1
2004-2005 "Postdoctoral position", Bristol Royal Infirmary, University of Bristol, UK
Structural characterization of human mucin O-glycans implicated in bacterial adhesion (Helicobacter pylori, Pseudomonas aeruginosa, Shigella flexneri…).
Study of the molecular dialogue between host and pathogens.
Identification of glycomimetics inhibiting carbohydrate-bacterial lectin interactions.
Modification of expression and glycosylation of mucins in colorectal cancer. Development of early diagnostic and prognostic mucin markers for colorectal cancer.
The mucosal surface is the primary interface between internal host tissues and the vast microbiota. Mucins, key components of mucus, are high molecular weight glycoproteins characterized by many O-linked oligosaccharides to the core polypeptide. They play many biological functions, helping to maintain cellular homeostasis and to establish symbiotic relationships with complex microbiota.
Alteration of mucin production and glycosylation occurs in numerous diseases such as IBD, cystic fibrosis, cancer or infectious diseases. What are the mechanisms explaining deregulation of mucin expression and glycosylation? What are the new functions played by these modified molecules? Do these alterations (neoexpressed mucins or O-glycans) have a diagnostic, prognostic or therapeutic value for the treatment of pathologies? These questions still remain unclear and are the basis of my research work.
My current research is also focused on a better comprehension of the molecular dialogue established between the host and commensal microbiota, pathogens and exogenous bacteria like probiotics. I try to elucidate mechanisms by which host cells or bacteria deregulate mucin biosynthesis in response to a bacterial colonization or infection. These studies should help better understand etiology of pathologies both correlated with a dysbiosis and structural modification of mucins.